Bayer's 54% Rally: Behind the Supreme Court Euphoria Lies a $32.5 Billion Debt, a $5 Billion Cash Drain, and an Antidumping Gamble
Published on 07/05/2026 at 05:04 | Redaktion boerse-global.de
Bayer is living a contradiction. The stock surged 54% in 30 days, rode a landmark Supreme Court ruling to a 52-week high just shy of €53.86, and then – within five days of that legal victory – fired a new salvo against Chinese glyphosate imports. Investors have cheered the courtroom reprieve, but the company’s financials are telling a far less celebratory story. Free cash flow cratered to minus €2.32 billion in the first quarter of 2026, nearly €800 million worse than the same period a year earlier. Net financial debt stands at €32.5 billion, and Chief Financial Officer Wolfgang Nickl has flagged roughly €5 billion in additional cash outflows this year for legal legacy costs alone. The multibillion-dollar settlement of $7.25 billion is still not final.
The euphoria rests on a specific legal foundation. On 25 June 2026, the US Supreme Court ruled 7-2 that consumers cannot sue Bayer for failing to label glyphosate with a cancer warning when the Environmental Protection Agency does not require one. The decision toppled a $1.25 million verdict and, after nearly a decade of litigation that consumed more than $10 billion in legal costs, finally loosened the noose around the company’s neck. Just five days later, on 30 June, the newly formed subsidiary Ruveon LLC – created by spinning off Bayer’s US glyphosate business – filed an antidumping and countervailing duty petition with the US Department of Commerce and the International Trade Commission, targeting cheap Chinese material. Bayer says it is now the only company still producing glyphosate inside the United States, and it argues that generic imports from China have depressed prices well below the historical median. The management had already warned at the 2025 earnings presentation that glyphosate sales could fall 2% to 6% in 2026.
The market has so far chosen to focus on the legal win rather than the deepening cash shortfall. The stock closed Friday at €53.04, just 1.52% below the 52-week high of €53.86 set on 3 July. Over seven days, Bayer climbed 13.80%; over 30 days, the gain was 53.74%. Since the start of the year, the shares are up 39.49%, and on a trailing twelve-month basis they have more than doubled – a rise of 103.41%. From the 52-week low of €25.09 struck on 6 August 2025, the recovery amounts to 111.36%. The velocity of the rally has pushed technical indicators deep into overbought territory. The 14-day relative strength index sits at 85.1, a level that historically precedes sharp reversals. The stock trades 36.50% above its 50-day moving average of €38.86 and a staggering 42.91% above the 200-day line of €37.11. Annualized 30-day volatility of 63.19% reflects the underlying nervousness.
Should investors sell immediately? Or is it worth buying Bayer?
That nervousness is well founded. The management has repeatedly left the door open to a capital increase, a step that would dilute existing shareholders. Whether that tool gets used depends entirely on the operating business generating enough cash to cover the legal outflows. The pharmaceutical pipeline offers one potential remedy. The FDA is reviewing Asundexian, a stroke-prevention drug, under an accelerated process, with a decision expected by the end of 2026. A positive approval would open a significant new revenue stream and could ease the pressure to raise equity. But it is not a near-term fix.
Chart-based support levels provide some technical ballast. If the stock corrects, the 50-day moving average near €39 serves as the first floor, followed by the 200-day line at €37.11. A retest of those levels would still leave the shares far above the 52-week low but would erase a portion of the recent explosive gains. On the upside, sustained momentum would require not only a clean legal closing but also tangible progress in the trade fight against China – the Commerce Department and ITC must first decide whether to open an investigation, and there is no timeline for that decision.
The next major catalyst is the court hearing on the class-action settlement, scheduled for 19 August 2026 in Missouri. Even if the judge approves the $7.25 billion deal, the agreement can still be appealed, meaning the legal saga could stretch on for years, as Bayer acknowledged in its quarterly report. For now, the stock is priced for a clean resolution and a new trade policy win. The balance sheet, however, continues to write a very different draft.
Ad
Bayer Stock: New Analysis - 5 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
